GLPwatch
Papers (12034)
Page 176 of 201, ranked by citation count.
- Semaglutide-Induced Symptomatic Remission in Ulcerative Colitis.
- Therapeutic efficacy, biomarker signatures, and translatability of semaglutide in the liver biopsy-confirmed GAN DIO-MASH mouse model.
- Single-dose pharmacokinetics of sublingual semaglutide in rats.
- Fibrillar and Micellar Aggregation of Semaglutide and Formation of a Chiral-Imprinted Glass.
- Leucine supplementation modulates body composition and early weight rebound during GLP-1 receptor agonist therapy in diet-induced obese mice.
- Real world study of GLP-1 receptor agonists in overweight or obese type 2 diabetes by using repeated measurement analysis of variance.
- Osteogenic effects of metformin and exenatide on bone regeneration in non-diabetic rats: A Micro-CT and histological study.
- Semaglutide vs. Bariatric Surgery: Comparing Costs and Clinical Outcomes in Patients With Diabetes and Obesity.
- Semaglutide versus resmetirom for noncirrhotic MASH with moderate to advanced fibrosis: a cost-effectiveness analysis.
- Tirzepatide and Autonomic Dysfunction: Insights From Postural Orthostatic Tachycardia Syndrome.
- Transient Hyperprolactinemia Associated With Semaglutide in a Patient With Hashimoto's Thyroiditis.
- Reply: Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial.
- Spontaneous Pneumomediastinum Associated with Semaglutide Therapy: A Case Report.
- Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial.
- Tirzepatide: Obesity injection will get phased rollout to avoid overwhelming GPs.
- Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.
- Obesity in patients without diabetes undergoing coronary artery bypass graft surgery: Time to select patients for semaglutide.
- The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model.
- Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial.
- Variable Effects of Glucagon Like Peptide-1 Receptor Agonists on Body Composition in Older Women.
- From evidence to practice: Identifying candidates for semaglutide in chronic atherosclerotic disease.
- The GLP-1 Receptor Agonist Liraglutide Promotes Anticancer Activities in MCF7 Breast and PC-3 Prostate Cancer Cells by Modulating Glycolysis, Oxidative Stress and Adipokines.
- Is liraglutide the solution for weight loss in women with polycystic ovarian syndrome?
- [Diabetes Mellitus Type 2: Recent Publications and New Drugs].
- [High dosage GLP-1 analogs are now available].
- Liraglutide. Type 2 diabetes: more prudent to continue using exenatide.
- Medication Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
- Efficacy of dulaglutide after switching from incretin-related drugs in patients with type 2 diabetes and inadequate glycemic control.
- [Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased].
- Unanticipated Adverse Events With Tirzepatide: Three Cases Underscoring the Importance of Postmarketing Monitoring.
- [Effect of byetta on renal osmoregulatory function in patients with diabetes mellitus].
- A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health.
- GLP-1 and Alcohol-Related Behaviors: Insights From Preclinical Studies.
- Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes.
- Pre-Treatment Concerns and Their Association With Functioning and Well-Being During Incretin-Based Therapy: A Cross-Sectional Study.
- Tirzepatide ameliorates type 2 diabetes-associated male reproductive dysfunction via modulation of the Nrf2/Keap1 pathway.
- Glucagon-like peptide-1 receptor agonists and the risk of surgical intervention in idiopathic intracranial hypertension: A propensity-matched cohort study.
- Managing post-bariatric hypoglycemia: a systematic review of pharmacological therapies.
- GLP-1 and dual GIP/GLP-1 agonists in obese patients with HFpEF: a systematic review and meta-analysis of RCTs.
- Hormonal Contraception and Initiation of Semaglutide Therapy.
- Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.
- [Pharmacological treatments for obesity : what does the future hold?]
- Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus.
- Glucagon-like peptide-1 analog, liraglutide, alters blood-testis barrier permeability in juvenile healthy rats.
- Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?
- Holistic Management of Obesity in Patients with Incidental Cancer After Unprovoked Deep Vein Thrombosis: A Cardiometabolic and Antithrombotic Framework.
- Longacting exenatide in diabetes: DURATION-3.
- Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials.
- Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes.
- GLP-1 agonists in glycemic and weight control of type 2 diabetes. New perspectives.
- The Effects of New Antidiabetic Drugs on the Course of Peripheral Arterial Occlusive Disease.
- Effect of tirzepatide on prediabetics and blood pressure with implications for future research.
- Clinical and metabolic profile of adults with obesity attending lifestyle medicine clinics.
- [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
- [Safety Management of Incretin-Based Obesity Therapy: Expert Consensus on the Use of Semaglutide and Tirzepatide].
- Targeted Ileal Bile Acid Transporter Inhibition as Rescue Therapy for Tirzepatide-Induced Severe Constipation: A Case Report.
- Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
- Liraglutid verzögert Diabetesentstehung.
- Tirzepatide-induced Weight Loss in Overweight or Obese Midlife Adults with and without Type 2 Diabetes: A Real-world Comparative Cohort Study.
- [Effect of liraglutide on interleukin-1β expression in the pancreatic islets of OLETF rats].